•  
  •  
 

Abstract

Background and Objectives: DM plays an important role in the endothelial dysfunction and vascular complications like dyslipidemia and atherosclerosis., It is important now a day to evaluate the dyslipidemic effects of oral hypoglycemic drugs in addition to blood glucose lowering effects, since this may provides a better treatment approach and participates in the prevention of complications of DM.Patients and Methods :We studied the dyslipidemic effects of glyburide, metformin, and their combination on (111) NIDDM patients aged from 39 – 58 years, treated for two years with different treatment lines and compared the results with healthy controls. Serum (TC-C), (TG-C),(HDL-C),(VLDL-C), and (LDL-C) levels were estimated as a marker of dyslipidemia in the serum utilizing lipid profile kit. Results: Serum TC-C, TG-C, LDL-C, and VLDL-C levels significantly reduced and serum HDL-C levels significantly elevated in patients used metformin alone and glyburide / metformin combination therapy so, maintained serum lipid profiles at levels closer to that of controls, while patients used glyburide as monotherapy significantly increased serum TG-C, TC-C, VLDL-C, and LDL-C levels and significantly decreased serum HDL-C levels in comparison to control group.Conclusion: Metformin / glyburide combination therapy and metformin monotherapy provide better protection against dyslipidemia associated with NIDDM patients than glyburide used alone, and hence better prevention of complications like atherosclerosis.

Article Type

Article

First Page

67

Last Page

77

Rights

Copyright (c) 2017 AL-QADISIYAH MEDICAL JOURNAL

Download

Share

COinS